Wellington Management Group LLP Decreases Stake in Stevanato Group S.p.A. (NYSE:STVN)

Wellington Management Group LLP decreased its stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 88.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 318,565 shares of the company's stock after selling 2,375,023 shares during the period. Wellington Management Group LLP owned 0.11% of Stevanato Group worth $6,942,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. TimesSquare Capital Management LLC raised its holdings in shares of Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company's stock valued at $71,657,000 after acquiring an additional 1,756,100 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Stevanato Group in the 4th quarter valued at about $20,239,000. Frontier Capital Management Co. LLC raised its holdings in shares of Stevanato Group by 1,012.0% during the 4th quarter. Frontier Capital Management Co. LLC now owns 1,003,235 shares of the company's stock valued at $21,860,000 after buying an additional 913,019 shares in the last quarter. Mutual of America Capital Management LLC purchased a new position in shares of Stevanato Group during the 4th quarter valued at about $13,848,000. Finally, Ranger Investment Management L.P. purchased a new position in shares of Stevanato Group during the 4th quarter valued at about $12,940,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Stephens raised Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. UBS Group reduced their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research report on Friday, March 7th. Finally, William Blair restated an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Stevanato Group presently has an average rating of "Moderate Buy" and an average target price of €25.70 ($29.20).

Stevanato Group Stock Up 2.4%

Shares of NYSE STVN traded up €0.56 ($0.64) during mid-day trading on Friday, hitting €23.80 ($27.05). 290,900 shares of the stock traded hands, compared to its average volume of 335,964. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.82) and a 52 week high of €25.75 ($29.26). The company has a market cap of $7.21 billion, a price-to-earnings ratio of 50.64, a PEG ratio of 7.18 and a beta of 0.53. The stock has a fifty day moving average price of €22.00 and a 200-day moving average price of €21.42.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). The business had revenue of €352.68 million during the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Research analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be paid a dividend of $0.0613 per share. This is a boost from Stevanato Group's previous annual dividend of $0.05. The ex-dividend date of this dividend is Thursday, June 5th. This represents a yield of 0.3%. Stevanato Group's payout ratio is presently 11.76%.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.